Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07410507 · ClinicalTrials.gov registry record · Phase 2
A Study of Brenipatide in Adult Participants With Schizophrenia
A Phase 2 study, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 450
- Enrollment target
NCT07410507 is a Phase 2 study that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 450 participants.
The verdict
NCT07410507, a Phase 2 study, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 450 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment period will last a maximum of 12 months, and the follow up period will last approximately 2 months. The length of time of your study participation may last up to approximately 15 months.
Interventions
- DRUG Placebo
- DRUG Brenipatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2026-02-10 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07410507
The ClinicalTrials.gov registry entry for NCT07410507 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07410507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07410507 about?
NCT07410507 is a clinical study titled "A Study of Brenipatide in Adult Participants With Schizophrenia". The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment pe...
What is the current status of trial NCT07410507?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 450 participants. The study started on 2026-02-10. Estimated completion is 2027-11.
What interventions are being tested in trial NCT07410507?
The interventions under investigation include: Placebo (DRUG), Brenipatide (DRUG).
Who is sponsoring clinical trial NCT07410507?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.